T1	p 74 140	patients with chemotherapy-induced painful peripheral neuropathy :
T2	p 468 680	8 National Cancer Institute ( NCI ) -funded cooperative research networks that enrolled 231 patients who were 25 years or older being treated at community and academic settings between April 2008 and March 2011 .
T3	p 894 1187	Eligibility required that patients have grade 1 or higher sensory neuropathy according to the NCI Common Terminology Criteria for Adverse Events and at least 4 on a scale of 0 to 10 , representing average chemotherapy-induced pain , after paclitaxel , other taxane , or oxaliplatin treatment .
T4	p 2283 2347	patients with painful chemotherapy-induced peripheral neuropathy
T5	i 16 26	duloxetine
T6	i 316 326	duloxetine
T7	i 430 448	placebo-controlled
T8	i 827 893	duloxetine followed by placebo or placebo followed by duloxetine .
T9	i 1279 1289	duloxetine
T10	i 1293 1300	placebo
T11	i 1354 1364	duloxetine
T12	i 1368 1375	placebo
T13	i 1461 1471	duloxetine
T14	i 1501 1508	placebo
T15	i 2050 2060	duloxetine
T16	i 2065 2072	placebo
T17	i 2156 2166	duloxetine
T18	i 2361 2371	duloxetine
T19	i 2386 2393	placebo
T20	o 30 67	pain , function , and quality of life
T21	o 346 369	average pain severity .
T22	o 1523 1587	chemotherapy-induced peripheral neuropathic pain . Pain severity
T23	o 1611 1660	Brief Pain Inventory-Short Form average pain item
T24	o 1684 1688	pain
T25	o 1840 1852	average pain
T26	o 2023 2041	average pain score
T27	o 2231 2235	pain
T28	o 2441 2447	pain .